JP2017538697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538697A5 JP2017538697A5 JP2017530168A JP2017530168A JP2017538697A5 JP 2017538697 A5 JP2017538697 A5 JP 2017538697A5 JP 2017530168 A JP2017530168 A JP 2017530168A JP 2017530168 A JP2017530168 A JP 2017530168A JP 2017538697 A5 JP2017538697 A5 JP 2017538697A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- cyano
- carbamimidoyl
- dichlorophenyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- -1 N'-cyano-N- {2- [2- (pyrrolidin-1-yl) ethoxy] -5- (trifluoromethyl) phenyl} carbamimidoyl Chemical group 0.000 claims 8
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 108010077895 Sarcosine Proteins 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- DRABPHUFBFTADU-UHFFFAOYSA-N 4-amino-N-[2-[N-cyano-N'-[3-(difluoromethoxy)phenyl]carbamimidoyl]-5-(3,4-dichlorophenyl)-3,4-dihydropyrazol-4-yl]-N-ethylbutanamide Chemical class NCCCC(=O)N(CC)C1C(=NN(C1)C(NC1=CC(=CC=C1)OC(F)F)=NC#N)C1=CC(=C(C=C1)Cl)Cl DRABPHUFBFTADU-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- GAPYHYWZUSFPBS-UHFFFAOYSA-N N-[2-[N'-[4-chloro-3-(difluoromethoxy)phenyl]-N-cyanocarbamimidoyl]-5-(3,4-dichlorophenyl)-3,4-dihydropyrazol-4-yl]-N-ethyl-2-hydroxyacetamide Chemical compound ClC1=C(C=C(C=C1)NC(=NC#N)N1N=C(C(C1)N(C(CO)=O)CC)C1=CC(=C(C=C1)Cl)Cl)OC(F)F GAPYHYWZUSFPBS-UHFFFAOYSA-N 0.000 claims 1
- 229940098750 SMYD2 inhibitor Drugs 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196766.1 | 2014-12-08 | ||
| EP14196766 | 2014-12-08 | ||
| EP15163993 | 2015-04-17 | ||
| EP15163993.7 | 2015-04-17 | ||
| PCT/EP2015/078912 WO2016091845A1 (en) | 2014-12-08 | 2015-12-08 | Novel aryl-cyanoguanidine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538697A JP2017538697A (ja) | 2017-12-28 |
| JP2017538697A5 true JP2017538697A5 (enExample) | 2019-01-24 |
Family
ID=54838348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530168A Pending JP2017538697A (ja) | 2014-12-08 | 2015-12-08 | 新規なアリール−シアノグアニジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10023539B2 (enExample) |
| EP (1) | EP3230274B1 (enExample) |
| JP (1) | JP2017538697A (enExample) |
| CN (1) | CN107207442A (enExample) |
| CA (1) | CA2969771A1 (enExample) |
| ES (1) | ES2722431T3 (enExample) |
| WO (1) | WO2016091845A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN109778407B (zh) * | 2019-02-18 | 2020-08-11 | 宁波荣昌祥服饰股份有限公司 | 一种抗菌面料及其制备方法 |
| CA3137218A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| CA3137610A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| CA3137611A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA3177214A1 (en) | 2020-03-31 | 2021-10-07 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| CN115998869B (zh) * | 2022-09-23 | 2025-08-05 | 华中科技大学同济医学院附属同济医院 | 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用 |
| CN116327748B (zh) * | 2023-04-21 | 2024-09-17 | 武汉科技大学 | 联合用药物在制备抗肿瘤药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE155129T1 (de) | 1990-01-31 | 1997-07-15 | Du Pont | Pyrazolin-, pyrazolidin- und hydrazinderivate mit wirkung gegenüber arthropoden |
| EP1648447A1 (de) * | 2003-07-15 | 2006-04-26 | Bayer HealthCare AG | Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen |
| DE102004061747A1 (de) * | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Thiophen-substituierte Pyrazoline |
| DE102004061751A1 (de) * | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Cyanoguanidin-substituierte Pyrazoline |
| DE102004061748A1 (de) * | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Azetidin-substituierte Pyrazoline |
| JP5881705B2 (ja) * | 2010-09-03 | 2016-03-09 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔの阻害のための新規化合物及び組成物 |
-
2015
- 2015-12-08 CN CN201580075621.9A patent/CN107207442A/zh active Pending
- 2015-12-08 ES ES15807653T patent/ES2722431T3/es active Active
- 2015-12-08 US US15/534,404 patent/US10023539B2/en active Active
- 2015-12-08 WO PCT/EP2015/078912 patent/WO2016091845A1/en not_active Ceased
- 2015-12-08 EP EP15807653.9A patent/EP3230274B1/en not_active Not-in-force
- 2015-12-08 JP JP2017530168A patent/JP2017538697A/ja active Pending
- 2015-12-08 CA CA2969771A patent/CA2969771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538697A5 (enExample) | ||
| JP2005536475A5 (enExample) | ||
| JP4592819B2 (ja) | 抗寄生虫剤 | |
| JP2017525757A5 (enExample) | ||
| RU2315041C2 (ru) | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения | |
| RU2312105C2 (ru) | N-пиразинилфенилсульфонамиды и их применение при лечении опосредованных хемокинами заболеваний | |
| JP2004517087A5 (enExample) | ||
| JP2007500226A5 (enExample) | ||
| JP2020506946A5 (enExample) | ||
| JP2017511794A5 (enExample) | ||
| JP2016533397A5 (enExample) | ||
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP2017505793A (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JP2017505790A (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JP2006504658A5 (enExample) | ||
| RU2009112598A (ru) | Модуляторы киназы, ассоциированной с рецептором интерлейкина-1 | |
| CZ20023264A3 (cs) | Deriváty oxazolu, způsob jejich výroby a použití a farmaceutický prostředek | |
| JP2020532550A5 (enExample) | ||
| JP2014525426A5 (enExample) | ||
| JP2018535235A5 (enExample) | ||
| JP2018535986A5 (enExample) | ||
| JP2010522770A5 (enExample) | ||
| CA2628844A1 (en) | Pyrazole derivatives and their medical use | |
| JP2017509694A5 (enExample) | ||
| CA3139228A1 (en) | (r)-3-(chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (bk) b2 receptor antagonist for treating skin diseases |